Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
NCT00170170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2010-02-02
Summary
This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.
Conditions
- Transplantation
- Infection
- Cytomegalovirus Infections
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY - lead OTHER
Principal Investigators
-
Raymund R. Razonable, M.D. · Mayo Clinic
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-11-30
- Primary Completion
- 2007-06-30
- Completion
- 2007-06-30
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
NCT01769170 ·Status: COMPLETED ·Phase: PHASE3
-
CMV-associated Immunomodulation in Renal Transplant Patients
NCT06976008 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of CMV in Kidney Transplant Recipients
NCT02061215 ·Status: TERMINATED
-
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
NCT06494033 ·Status: RECRUITING
-
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
NCT04690933 ·Status: COMPLETED
-
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates
NCT00677482 ·Status: COMPLETED
-
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
NCT01473849 ·Status: UNKNOWN
-
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
NCT00273143 ·Status: COMPLETED
-
Cell-mediated Immunity for Prevention of CMV Disease
NCT02538172 ·Status: COMPLETED ·Phase: NA
-
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
NCT06075745 ·Status: RECRUITING ·Phase: PHASE2
-
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
NCT05576805 ·Status: COMPLETED
-
Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients
NCT00198224 ·Status: COMPLETED ·Phase: NA
-
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
NCT06133010 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
NCT05958186 ·Status: COMPLETED
-
PREDICT Cytomegalovirus (CMV)
NCT03300882 ·Status: COMPLETED
-
Study of Prophylactic Vs Preemptive Valganciclovir
NCT00374686 ·Status: COMPLETED ·Phase: NA
-
Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
NCT00364052 ·Status: UNKNOWN
-
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
NCT00817908 ·Status: COMPLETED
-
The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
NCT00275665 ·Status: COMPLETED ·Phase: PHASE3
-
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
NCT01509404 ·Status: COMPLETED ·Phase: PHASE4
-
Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients
NCT00225394 ·Status: COMPLETED
-
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
NCT06407232 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
NCT07266467 ·Status: RECRUITING ·Phase: PHASE4
-
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
NCT07096453 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
NCT06066957 ·Status: RECRUITING ·Phase: PHASE2